Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1 AND Treatment
187 results:

  • 1. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
    Pan QZ; Zhao JJ; Liu L; Zhang DS; Wang LP; Hu WW; Weng DS; Xu X; Li YZ; Tang Y; Zhang WH; Li JY; Zheng X; Wang QJ; Li YQ; Xiang T; Zhou L; Yang SN; Wu C; Huang RX; He J; Du WJ; Chen LJ; Wu YN; Xu B; Shen Q; Zhang Y; Jiang JT; Ren XB; Xia JC
    Signal Transduct Target Ther; 2024 Apr; 9(1):79. PubMed ID: 38565886
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. High-tissue FRMD6 expression predicts better outcomes among colorectal cancer patients.
    von Koskull A; Hagström J; Haglund C; Kaprio T; Böckelman C
    Biomarkers; 2024 May; 29(3):127-133. PubMed ID: 38385211
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Long-term outcomes of endoscopic or surgical resection in T1 colorectal cancer patients: a retrospective cohort study.
    Song S; Dou L; Zhang Y; Liu X; Liu Y; He S; Wang G
    Surg Endosc; 2024 Mar; 38(3):1499-1511. PubMed ID: 38242989
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
    Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
    Zhu C; Han G; Wu B
    BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. MicroRNAs Regulate Inhibitor of Apoptosis Proteins (IAPs) in colorectal cancer.
    Tanzadehpanah H; Avan A; Ghayour-Mobarhan M; Ferns GA; Manoochehri H; Sheykhhasan M; Mahaki H
    Microrna; 2023; 12(3):210-220. PubMed ID: 37718526
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A quality improvement project to optimize access to psychosocial care for cancer survivors who experience fear of recurrence.
    Pereira L; Nguyen P; Benea A; Townsley C
    J Psychosoc Oncol; 2023; 41(6):721-731. PubMed ID: 37702764
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Radiation Therapy Changed the Second Malignancy Pattern in Rectal cancer Survivors.
    Ye X; Tan Y; Ma R; Lou P; Yuan Y
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629753
    [No Abstract]    [Full Text] [Related]  

  • 9. Anastasis enhances metastasis and chemoresistance of colorectal cancer cells through upregulating ciap2/NFκB signaling.
    Wang R; Wang Y; Liu X; Liu M; Sun L; Pan X; Hu H; Jiang B; Zou Y; Liu Q; Gong Y; Wang M; Sun G
    Cell Death Dis; 2023 Jun; 14(6):388. PubMed ID: 37391410
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line treatment of Metastatic colorectal cancer.
    Barufaldi LA; de Albuquerque RCR; do Nascimento A; Martins LFL; Zimmermann IR; de Souza MC
    Value Health Reg Issues; 2023 Sep; 37():33-40. PubMed ID: 37207532
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Changing trends, clinicopathological characteristics, surgical treatment patterns, and prognosis of schistosomiasis-associated versus non-schistosomiasis-associated colorectal cancer: a large retrospective cohort study of 31 153 cases in Shanghai, China (2001-2021).
    Zheng N; Wang H; Yu Q; Wang C; Bai CG; Pan AF; Jiang J; Lu J; Dai SM; Mei Z; Zhang W; Gao XH
    Int J Surg; 2023 Apr; 109(4):772-784. PubMed ID: 36999800
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Immune Activation following Irbesartan treatment in a colorectal cancer Patient: A Case Study.
    Titmuss E; Milne K; Jones MR; Ng T; Topham JT; Brown SD; Schaeffer DF; Kalloger S; Wilson D; Corbett RD; Williamson LM; Mungall K; Mungall AJ; Holt RA; Nelson BH; Jones SJM; Laskin J; Lim HJ; Marra MA
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982943
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Has_circ_0071803 promotes colorectal cancer progression by regulating miR-330-5p/MAPK signaling pathway.
    Huang L; Dou G; Lu J; Chen Z; Wang J
    Histol Histopathol; 2023 Dec; 38(12):1443-1451. PubMed ID: 36856372
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Bevacizumab treatment for Metastatic colorectal cancer in Real-World Clinical Practice.
    Dinu IM; Mihăilă M; Diculescu MM; Croitoru VM; Turcu-Stiolica A; Bogdan D; Miron MI; Lungulescu CV; Alexandrescu ST; Dumitrașcu T; Buică F; Luca IN; Lungulescu C; Negulescu MC; Gramaticu IM; Cazacu IM; Croitoru AE
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837551
    [No Abstract]    [Full Text] [Related]  

  • 15. [Associations of genetic variations in pyroptosis related genes with acute adverse events in postoperative rectal cancer patients receiving concurrent chemoradiotherapy].
    Chen HX; Ren NX; Yang J; Chen JN; Lu QX; Feng YR; Huang Y; Yin LL; Lin DX; Li YX; Jin J; Tan W
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):146-152. PubMed ID: 36781235
    [No Abstract]    [Full Text] [Related]  

  • 16. Integrated proteomic and phosphoproteomic analysis for characterization of colorectal cancer.
    Zhu H; Li Y; Guo J; Feng S; Ge H; Gu C; Wang M; Nie R; Li N; Wang Y; Wang H; Zhong J; Qian X; He G
    J Proteomics; 2023 Mar; 274():104808. PubMed ID: 36596410
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Systemic Chemotherapy With or Without Hepatic Arterial Infusion Chemotherapy for Liver Metastases From Pancreatic cancer: A Propensity Score Matching Analysis.
    Ouyang H; Ma W; Si T; Liu D; Chen P; Gerdtsson AS; Song J; Ni Y; Luo J; Yan Z
    Clin Colorectal Cancer; 2023 Mar; 22(1):111-119. PubMed ID: 36473779
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Efficacy and safety of self-expandable metal stent placement for treatment of primary and metastatic gastric outlet obstruction.
    Lai H; Wu K; Liu Y; Li D; Peng T; Zhang B
    Ir J Med Sci; 2023 Oct; 192(5):2077-2084. PubMed ID: 36441448
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Between-Hospital and Between-Physician Variation in Outcomes and Costs in High- and Low-Complex Surgery: A Nationwide Multilevel Analysis.
    Salet N; Stangenberger VA; Bremmer RH; Eijkenaar F
    Value Health; 2023 Apr; 26(4):536-546. PubMed ID: 36436789
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The clinical experience of the prognosis in opposite CEA and image change after therapy in stage IV colorectal cancer.
    Su YT; Chen JW; Chang SC; Jiang JK; Huang SC
    Sci Rep; 2022 Nov; 12(1):20075. PubMed ID: 36418865
    [TBL] [Abstract] [Full Text] [Related]  


    of 10.